Elaboration of tumor necrosis factor (TNF) is a very early event in development of ischemia/reperfusion injury pathophysiology. Therefore, TNF may be a prominent mediator of endothelial cell and vascular wall dysfunction in sickle cell anemia, a hypothesis we addressed using NY1DD, S1S Antilles , and SS-BERK sickle transgenic mice. Transfusion experiments revealed participation of abnormally activated blood monocytes exerting an endothelial activating effect, dependent upon Egr-1 in both vessel wall and blood cells, and upon NFjB(p50) in a blood cell only. Involvement of TNF was identified by beneficial impact from TNF blockers, etanercept and infliximab, with less benefit from an IL-1 blocker, anakinra. In therapeutic studies, etanercept ameliorated multiple disturbances of the murine sickle condition: monocyte activation, blood biomarkers of inflammation, low platelet count and Hb, vascular stasis triggered by hypoxia/reoxygenation (but not if triggered by hemin infusion), tissue production of neuro-inflammatory mediators, endothelial activation (monitored by tissue factor and VCAM-1 expression), histopathologic liver injury, and three surrogate markers of pulmonary hypertension (perivascular inflammatory aggregates, arteriolar muscularization, and right ventricular mean systolic pressure). In aggregate, these studies identify a prominent-and possibly dominantrole for an abnormal monocyte-TNF-endothelial activation axis in the sickle context. Its presence, plus the many benefits of etanercept observed here, argue that pilot testing of TNF blockade should be considered for human sickle cell anemia, a challenging but achievable translational research goal.
| I N TR ODU C TI ON
A chronic and robust systemic inflammatory state is a striking feature and pathogenic factor in sickle cell anemia (SCA). 1 Hence, identification of the core vector(s) underlying inflammation's evolution and perpetuation should identify useful therapeutic targets. As general underlying processes, attention has focused upon vascular occlusion as the initiator of ischemia/reperfusion injury (I/R) pathophysiology 2 and upon hemolysis as a source of toxic heme. 3, 4 Beyond this, however, the role of specific mediators as antecedent agents remains opaque in its intricacy. Indeed, available data on SCA do not even enable parsing potential mediators into those acting proximately versus more distally.
The literature on SCA, however, does document abnormal activation of blood monocytes and their ability to activate and/or damage vascular endothelial cells in vitro. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] This suggests monocyte prominence in clinical disease genesis, if only because monocyte/macrophages are dominant generators of pro-inflammatory cytokines in the broad context of inflammation's generative role in vascular disease generally. 18 The present studies implicate a disease causing vector extending from peripheral blood monocytes (PBM) to the vascular endothelium, with the bridging mediator being tumor necrosis factor (TNF, aka TNFa).
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Our focus upon TNF stems from its roles as a "sentinel cytokine," largely post-transcriptionally regulated, and as an acute-phase initiator of oxidant species and NFjB-driven (and other) responses that have defensive, beneficial roles. 19 Yet, its obverse, maladaptive potential can be realized when TNF is produced in excess and/or absent appropriate resolution. Then, its pleiotropic effects can induce multi-faceted inflammatory pathology. Thus, it is the striking clinical benefit of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases 19, 20 that prompts our interest in this approach to the stubborn chronicity of the SCA inflammatory state. Yet, the perplexing complexity of TNF biology makes efficacy of TNF-blocking agents impossible to predict with assurance.
This deserves exploration because many well-known TNF effects are directly relevant to pathobiology of clinical sickle disease. To illustrate, we simply focus upon the vascular endothelium, the blood/tissue interface of enormous importance in multiple biological processes.
Most globally harmful, TNF causes degradation of the glycocalyx, 21 thus jeopardizing its critical roles that include: mediation of sheardependent functions (e.g., NO production); anchorage of surface enzymes; and repelling potentially adherent blood cells. Separately, TNF jeopardizes NO bioavailability by activating both endothelial arginase (starving eNOS of its required substrate, arginine 22 ) and endothelial NADPH oxidase (depleting tetrahydrobiopterin to provoke superoxide generation by eNOS 23 ). Experimentally, TNF induces endothelial adhesion molecule expression to promote RBC adhesion 24 and vasoocclusion. 25 Infliximab is a chimeric, mouse/human hybrid monoclonal specific for TNF. Dosing here (10 mg/kg) would achieve the same fold-excess as for our highest-dose etanercept. The typical human dose is 3 mg/kg, given IV, every few weeks.
Anakinra, a recombinant form of the human IL-1 receptor antagonist, blocks signaling by IL-1a and IL-1b. We examined it because of prior use of an (undefined) IL-1 blocker by Kaul et al. 38 Dosing here was 10 mg/kg, with unknown ratio to IL-1 receptor. Anakinra is known to impede experimental murine inflammation.
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Scrambled Control Peptide, obtained via custom synthesis, contains the 12 amino acids of the terminal end of the TNFR2 in scrambled order.
For simplicity and to economize on animal consumption, this was always given at 0.1 mg/kg per dose, on same schedule as the other agents.
| Mice
Mice were housed and bred in our institution's specific-pathogen-free facility, with routine surveillance testing, to avoid confounding infectious disease. Studies were done with the approval of our Institutional Animal Care and Use Committee. We used NY1DD, S1S Antilles and SS-BERK sickle transgenic mice exhibiting, respectively, mild to moderate to severe phenotypes. 34 For NY1DD and S1S Antilles mice we used C57BL/6 controls. For mixed background BERK mice, our breeding strategy ensured background homogenization between SS-BERK and their AA-BERK controls.
| Cross-breeding
We separately crossbred knockout states for NFjB(p50) 14 and Egr-1 40 into NY1DD mice, using the same strategy we previously described.
14 Additionally, we crossbred the NFjB(p50) knockout into S Antilles mice.
Then NFjB(p50)-/-NY1DD and NFjB(p50)-/-S Antilles were crossbred to ultimately obtain NFjB(p50)-/-S1S Antilles mice. Such knockout transfers always included >10 backcrosses against wild-type C57BL/6.
| Marrow transplantation
As described, 14 we previously conducted reciprocal marrow transplantations between wild-type and NFjB(p50)2/2 NY1DD to obtain NY1DD mice having NFjB(p50)2/2 in blood cells but not endothelium/tissue, or conversely having NFjB(p50)2/2 in endothelium/tissue but not blood cells. Using the same strategy, we here created NY1DD mice that were Egr-1-/-in blood cells but not endothelium/tissue, or vice versa.
| Study protocols
We tested the impact of drugs, transcription factor knockouts, or transfusion of PBMC using animals at 3. 
| Long-term therapeutic studies
We treated S1S Antilles with etanercept (3 mg/kg, sq, once weekly, for 13 weeks), while BERK mice received higher dosing (3 mg/kg for 3 weeks or 6 mg/kg for 6 weeks, sq, twice weekly).
| Endpoints examined 2.4.1 | Blood counts and inflammatory markers
We performed CBC on cardiac blood using an analyzer standardized for murine blood. We used ELISA kits to assess plasma biomarker levels, and FACS to detect monocyte activation.
| Endothelial cell activation
We monitored expression of Tissue Factor (TF; expressed as the percent of pulmonary veins positive) and vascular cell adhesion molecule 1 (VCAM-1; expressed as percent of 50 6 10 lm microvessels having >50% circumferential positivity). 34 
| Vascular stasis
Using S1S Antilles mice with implanted dorsal skinfold chambers, we determined the percentage of previously-flowing microvessels that developed vascular stasis after provocation with either H/R or infusion of hemin. 3 Some were pretreated with etanercept.
| Dermal Cytokines/neuropeptides
We tested cytokine/neuropeptide levels in conditioned medium from skin biopsies (obtained from long-term etanercept-treated SS-BERK mice) that were incubated ex vivo for 24 hours, as described. 41 
| Peri-vascular inflammatory aggregates
We used antibodies to CD11b and von Willebrand Factor (vWF) to identify CD11b1 cells that were perivascular. We discovered this abnormality only retrospectively, so retrievable data are from frozen lung sections that were not prepared with prospective intent to quantify lesion prevalence.
| Pulmonary arteriolar muscularization
The same caveat applies here as well. We used antibodies to murine smooth muscle actin (SMA) and vWF to score 50 6 10 lm microvessels as non-muscular, partially muscular, or fully muscular. A single value for each mouse was derived from at least 50 vessels from three separated sections.
| Measurement of RVSP (right ventricular mean systolic pressure)
Using isoflurane anesthesia, standardized mechanical ventilation, and a para-sternal lateral thoracotomy, 42 we placed a right ventricular pressuretransducing catheter to capture waveform data that enabled calculation of RVSP. We measured multiple parameters to assess RV mass.
| Statistics
We made data comparisons using t testing, paired or unpaired, ANOVA as indicated.
| R ESU L TS
We studied transgenic sickle mouse models having phenotypes ranging from mild to severe: NY1DD, S1S Antilles and SS-BERK. 34 We identified endothelial activation by monitoring endothelial expression level of tissue factor (TF) and VCAM-1. Studies utilized TNF blocker etanercept (E), with a control peptide (CP) always examined in parallel; the latter uniformly failed to exert any effect compared to no treatment. Therefore, to simplify graphics, we focus upon only the most important com-
parisons. An interpretation of individual experiment sets is included within Results, so Discussion can address the broader issues. here sought to corroborate this using sickle mice that spontaneously exhibit an inflammatory state, i.e., not requiring challenge by a stressor.
| I D EN TI F I CA TI ON OF A M ONOC YTE -TN F -EN DOT HE LI

| S1S Antilles mice
Infusion of PBMC from S1S Antilles donors ( Figure 1B . This is supportive because we previously had demonstrated, using NY1DD mice, that NFjB(p50)-/-eliminates ability of PBMC to activate endothelium. 14 
| SS-BERK mice
Using BERK mice, we also identified the activating role of PBMC on endothelial TF ( Figure 1C ), as well as endothelial VCAM-1 ( Figure 1D ).
In AA-BERK recipients, activation of both endothelial antigens resulted from infusion of PBMC from SS-BERK donors (bars 2) but not from AA-BERK control donors (bars 1).
| Endothelial activation is TNF-dependent in sickle mice
We identified involvement of TNF first using the H/R stressed NY1DD mice that developed increased expression of both TF and VCAM-1 Figure S1 ). These findings are consistent, respectively, with Egr-1 0 s known prominence as a regulator of TF expression 43 and with its suspected role in monocyte TNF expression. 44 
| NFjB(p50)
We previously reported that the impact of PBM on endothelial TF expression actually requires a NFjB(p50) dependent gene within blood cells. 14 It is relevant that NFjB(p50) is believed to participate indirectly in PBM production of TNF. 45 Interestingly, however, we have now observed that NFjB(p50)-/-in sickle mice actually causes increased expression of endothelial VCAM-1 (Supporting Information Figure S1 ).
This can be explained simply by the NFjB p50/p65 heterodimer's less robust promotion of gene expression, compared to that of the NFjB p65/p65 homodimer. 46 Hence, a knockout of p50 effectively removes a braking effect.
| NFjB inhibitors
These data suggest it may be advisable to avoid NFjB inhibitors that are truly specific for the p50 component. Fortunately, most are not p50 specific. Nonetheless, we here examined the VCAM-1 expression impact of the NFjB inhibitors we previously identified as effective inhibitors of endothelial TF in sickle mice. 14, 34, 47 We find several of those agents to be effective also in ameliorating the increased VCAM-1 in post-H/R NY1DD mice: lovastatin, andrographolide, curcumin, sulfasalazine and histone deacetylase inhibitors (Supporting Information   Table S1 ).
This VCAM-1 expression scoring was enabled by our discovery, during the course of these studies of an unsuspected, regional heterogeneity in the dynamism of VCAM-1 0 s activation in sickle mice.
VCAM-1 responses, both increases and inhibitions, were detectable
only by focusing on vessels 50 6 10 lm diameter.
| T HE RA P E U TI C BE N EF I T F R OM TN F B LOCKA D E
To assess etanercept in a therapeutic context, we conducted long-term studies giving etanercept vs. control peptide to S1S Antilles or SS-BERK mice. Doses, schedules and length of treatment are described in Methods. Etanercept exerted a beneficial impact upon nearly all of the endpoints evaluated as being relevant to human sickle disease. Long-term treatment of S1S Antilles mice with etanercept also improved blood Hb and platelet count. An abnormally low platelet count is a feature of murine sickle models (Supporting Information   Table S2 ), as it is in some humans with sickle cell anemia.
| Pulmonary endothelial activation state
Etanercept was an effective inhibitor of abnormal pulmonary endo- 
| Neuro-inflammatory mediators and pain
In vitro incubation of skin biopsies from SS-BERK mice that had been treated long-term with control peptide or etanercept enabled quantitative measurement of neuro-inflammatory mediator elaboration from actual tissue. As previously reported, such data actually correlate with pain behaviors exhibited by sickle mice. 41 Biopsies from the etanercept-treated mice exhibited decreased elaboration of IL-6, MCP-1, substance P and CGRP (calcitonin gene-related peptide) (Supporting Information Figure S2 ). Although not achieving significance due to small number of animals available, levels of IL-1b, IL-1a, IFNg, and MIP-1a suggested a downwards trend.
We know that the biologies of acute and chronic pain both involve inflammation having complicated, bidirectional effects between systemic and neuro-inflammatory substances. 31, 32 Pain behaviors could not be tested here, as the number of available animals was far too
small. Yet, the present data suggest that therapy with etanercept might benefit pain.
| Histopathology
In contrast to an absence of pathology in C57BL6 control mice, livers of S1S Antilles mice displayed acute or chronic coagulative necrosis, indicating ischemia or prior infarction. This was ameliorated both by longterm treatment with etanercept and, revealingly, by presence of the NFjB(p50)-/-state (Supporting Information Table S2 ).
| Vascular occlusion
To assess etanercept impact upon acute vascular flow deficiency, we studied S1S Antilles mice bearing dermal windows (to enable microvascular flow visualization). We pretreated them with etanercept or control peptide and then challenged them with an insult known to trigger vascular stasis, either H/R 2,14,34 or infusion of hemin. 3 The stasis triggered by H/R was greatly diminished by etanercept ( Figure 3A ), but that triggered by hemin infusion was not blunted significantly ( Figure   3B ). This is consistent with our current understanding of these two stasis induction mechanisms. H/R exposure triggers I/R 14,34 which involves TNF elaboration in its very earliest stages. In contrast, hemin directly perturbs endothelium, causing stasis via TNF-independent mechanisms in addition to TNF elaboration. 3 
| Pulmonary arterial disease
We examined three surrogate markers for presence of pulmonary hypertension.
| Peri-vascular inflammatory aggregates
Staining for CD11b1 evinced the presence of perivascular inflammatory cell aggregates (examples shown in Supporting Information Figure S3 ). Since the available material allowed only semi-quantitation, we applied three different measures (Table 2) . Each parameter revealed increased prevalence of these inflammatory aggregates in S1S Antilles compared to C57Bl6 control, and each was notably diminished in response to etanercept. Because such perivascular inflammatory aggregates are part of the histopathology of human pulmonary hypertension, 48 this result prompted the following additional studies.
| Pulmonary arteriolar muscularization
Staining for smooth muscle actin (SMA) (examples shown in Supporting Information Figure S3 ) suggested a trend towards increasing muscularization of 50 lm pulmonary arterial vessels as animals matured from age 1 to 4 months, seen for both C57BL6 and S1S Antilles mice ( Figure   4A ). However, at both ages, muscularization was greater for sickle than for normal mice. Notably, after 3 months of etanercept therapy (starting at age 1 month) the muscularization in S1S Antilles mice was significantly reduced. Indeed, it appears the etanercept may have both prevented further muscularization and somewhat reduced existing muscularization. exert activating effects via TLR4 on monocytes, leading to TNF release;
| Elevated right ventricular pressure
and TNF actually enhances activity of this TLR4 pathway. 55 This would seem to predict the very cyclicity and apparent perpetuity of inflammation that is evident in SCA.
| Why TNF blockade should work in sickle disease
The remarkably uniform efficacy of etanercept seen here is, we suspect, not because it is exerting "anti-inflammatory" effects in the traditional sense. Rather, it is impeding the actual triggers that comprise the very inception of I/R pathobiology. 2 If so, TNF blockade would inhibitperhaps even halt-the very driver of the perpetual inflammatory process responsible for the vascular dysfunction of SCA. If this I/R model of SCA pathophysiology 2 is valid, TNF can be expected to be ameliorative.
| What next?
The unavoidable uncertainty inherent in the complexity of TNF biology also complicates therapeutic predictability. Beyond data such as ours, only advancing to pilot study in humans can answer whether or not etanercept may exert benefit for SCA. This, however, may require our field to create solutions to several barriers, as we expect efficacy of etanercept might be exerted over longer rather than shorter timescales. Additionally, nature and mechanism of benefit could be different for acute intervention vs. chronic prevention.
Finally, we are not arguing that etanercept itself would be an ideal therapeutic, because it is expensive and must be administered subcutaneously, although it could be deployed immediately in health systems that can deal with such issues. As alternatives, ongoing development of small molecule TNF blockers may eventually offer very wide applicability and accessibility. Meanwhile, it would be helpful for us to glean insights about pathophysiology that would derive from a focused pilot test of etanercept in humans with SCA. Attempting that would present several significant challenges for which solutions have been proposed elsewhere. Indeed, that might identify additional opportunities for productive therapeutic targeting.
